[1]Braak H, Sastre M, Bohl JR, et al. Parkinson’s disease: lesions in dorsal horn layer Ⅰ, involvement of parasympathetic and sympathetic pre-and postganglionic neurons[J]. Acta Neuropathol, 2007, 113(4): 421-429.
[2]Kadhim S, Pringsheim T, Le A, et al. Validating screening tools for depression in Parkinson’s disease[J]. Mov Disord, 2018, 33(7): 1184-1186.
[3]Cury RG, Carvalho MJ, Lasteros F, et al. Effects of subthalamic stimulation on olfactory function in Parkinson disease[J]. World Neurosurg, 2018, 114:e559-e564.
[4]Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson’sdisease—a multicenter study[J]. Parkinsonism Relat Disord, 2009, 15(7): 490-494.
[5]Brodoehl S, Klingner C, Volk GF, et al. Decreased olfactory bulb volume in idiopathic Parkinson’s disease detected by 3.0-tesla magnetic resonance imaging[J]. Mov Disord, 2012, 27(8): 1019-1025.
[6]Kurlan R, Kim MH, Gash DM. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism[J]. Mov Disord, 1991, 6(2): 111-118.
[7]Cheng W, Ren ZhH, Guan YQ, et al. Impact on the dopaminergic neurons of olfactory bulb in cynomolgus monkeys damaged by MPTP[J]. Acta Anatomica Sinica, 2014, 45(3): 333-337. (in Chinese)
程炜,任振华,关云谦,等. 1-甲基-4-苯基-1,2,3,6-四氢吡啶对食蟹猴嗅球多巴胺能神经元的影响[J]. 解剖学报, 2014,45(3): 333-337.
[8]Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis[J]. Mov Disord, 2001, 16(1): 41-46.
[9]Haehner A, Hummel T, Reichmann H. A clinical approach towards smell loss in Parkinson’s disease[J]. J Parkinsons Dis, 2014, 4(2): 189-195.
[10]Sharifi H, Mohajjel NA, Farajnia S, et al. Effect of buspirone, fluoxetine and 8-oh-dpat on striatal expression of Bax, Caspase-3 and Bcl-2 proteins in 6-hydroxydopamine-induced hemi-Parkinsonian rats[J]. Adv Pharm Bull, 2015, 5(4): 491-495.
[11]Liu Y, Guo Y, An S, et al. Targeting Caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson’s disease[J]. PLoS One, 2013, 8(5): e62905.
[12]Yamada M, Kida K, Amutuhaire W, et al. Gene disruption of caspase-3 prevents MPTP-induced Parkinson’s disease in mice[J]. Biochem Biophys Res Commun, 2010, 402(2): 312-318.
[13]Edlich F. BCL-2 proteins and apoptosis: recent insights and unknowns[J]. Biochem Biophys Res Commun,2018, 500(1): 26-34.
[14]Sridharan S, Mohankumar K, Jeepipalli SP, et al. Neuroprotective effect of valeriana wallichii rhizome extract against the neurotoxin MPTP in C57BL/6 mice[J]. Neurotoxicology, 2015, 51: 172-183.
[15]Ahmed Z, Shaw G, Sharma VP, et al. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry[J]. J Histochem Cytochem,2007, 55(7): 687-700.
[16] Che Y, Hou L, Sun F, et al. Taurine protects dopaminergic neurons in a mouse Parkinson’s disease model through inhibition of microglial M1 polarization[J]. Cell Death Dis, 2018, 9(4): 435.
|